Vesicular stomatitis virus Pseudotyped with SARS-CoV-2 Spike Glycoprotein

Cat #: EG-351

   

Qty   
Product Name Vesicular Stomatitis Virus (VSV) Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Stabilized Trimer
Description Vesicular stomatitis virus particles pseudotyped with SARS-CoV-2 spike glycoprotein, with hexaPro mutations so the surface protein antigenically optimal pre-fusion conformation, produced and purified from HEK 293 cells.
Mutations Furin site RRAR mutated to GSAS; HexaPro mutations (K986P, V987P, F817P, A892P, A899P and A942P) to ensure the S glycoprotein remains in an antigenically optimal pre-fusion conformation
Source
HEK293T cells
Reporter
EGFP
Application
  • Screening of SARS-CoV-2 neutralizing antibodies
  • Assessment of vaccine efficacy
Titer > 1 X 107 RFU/ml or > 1 X 105 TU/ml
Shipping Dry ice
Storage -80 oC
References
Generation of VSV Pseudotypes Using Recombinant ΔG-VSV for Studies on Virus Entry, Identification of Entry Inhibitors, and Immune Responses to Vaccines Sci Rep 10, 19076 (2020). doi:10.1016%2Fj.jviromet.2010.08.006